SCHEMBL23934265

SCHEMBL23934265

CN1C(=O)c2c(NC(=O)c3ccc(C#N)cc3)ccc(NC(=O)c3ccc(C#N)cc3)c2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MMP1 P03956 1/20 0.48
LMNA P02545 3/20 0.47
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
DEGS1 O15121 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
GPR35 Q9HC97 1/20 0.46
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PKM P14618 2/20 0.45
MLYCD O95822 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
NAMPT P43490 1/20 0.42
DPP4 P27487 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934214 0.82 LMNA (0.53) POLBRXFP1MMP1LMNAMAPT
SCHEMBL23934205 0.80 POLB (0.53) POLBLMNAMAPTTP53KMT2A
SCHEMBL23934283 0.79 POLB (0.49) POLBRXFP1MMP1DEGS1CYP11B1
SCHEMBL23934284 0.77 MAPT (0.53) LMNAMAPTTP53CYP11B1CYP11B2
SCHEMBL8417469 0.75 MMP1 (0.65) POLBRXFP1MMP1LMNAMAPT
SCHEMBL12501958 0.73 RAB9A (0.56) POLBRXFP1LMNAMAPTKMT2A
SCHEMBL12945374 0.71 KCNMA1 (0.68) POLBRXFP1MAPTTP53KMT2A
SCHEMBL9337665 0.71 MLYCD (0.76) POLBLMNAMAPTCYP11B1CYP11B2
SCHEMBL6263516 0.71 MLYCD (0.76) POLBLMNAMAPTCYP11B1CYP11B2
SCHEMBL6359401 0.71 ALB (0.63) POLBRXFP1LMNAMAPTGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885RXFP1 2817/4885MMP1 4347/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885RXFP1 2817/4885MMP1 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.